Literature DB >> 8091622

Comparative efficacy of moxidectin and ivermectin against hypobiotic and encysted cyathostomes and other equine parasites.

L Xiao1, R P Herd, G A Majewski.   

Abstract

Efficacies of moxidectin and ivermectin were compared in four groups of eight ponies with natural parasite infections: placebo (Control), oral moxidectin gel at 0.3 mg kg-1 of body weight (Mox 0.3), oral moxidectin gel at 0.4 mg kg-1 of body weight (Mox 0.4), and oral ivermectin paste at 0.2 mg kg-1 of body weight (Ivermectin). Fecal samples were taken 0 and 2 weeks after treatment. Animals were necropsied and worms were collected 2 weeks after treatment. Moxidectin and ivermectin showed similar efficacy (99%) against adult cyathostomes, Strongylus spp., Triodontophorus spp. and Habronema muscae. Both drugs were also more than 98% effective against luminal cyathostome and Oxyuris equi fourth stage larvae (L4). Neither drug was effective (0-10.1%) against hypobiotic early third stage cyathostome larvae (EL3). Moxidectin was moderately effective (62.6-79.1%) in removing encysted cyathostome late third stage larvae (LL3) and L4, whereas ivermectin was ineffective (0%) against these stages. By contrast, ivermectin was 95.4% effective against Gasterophilus spp. third instar stage, whereas moxidectin was only 0-20.4% effective.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8091622     DOI: 10.1016/0304-4017(94)90020-5

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  11 in total

1.  Comparative long-term efficacy of ivermectin and moxidectin over winter in Canadian horses treated at removal from pastures for winter housing.

Authors:  Johanne Elsener; Alain Villeneuve
Journal:  Can Vet J       Date:  2009-05       Impact factor: 1.008

2.  Predatory activity of the fungus Duddingtonia flagrans in equine strongyle infective larvae on natural pasture in the Southern Region of Brazil.

Authors:  Gisane Lanes de Almeida; Janio Morais Santurio; José Osvaldo Jardim Filho; Régis Adriel Zanette; Giovana Camillo; Alexandra Geyer Flores; José Henrique Souza da Silva; Mário Luiz de la Rue
Journal:  Parasitol Res       Date:  2011-07-12       Impact factor: 2.289

3.  Equine cyathostomins: a review of biology, clinical significance and therapy.

Authors:  Susan Corning
Journal:  Parasit Vectors       Date:  2009-09-25       Impact factor: 3.876

4.  A field survey on anthelmintic resistance in equine small strongyles in Norway.

Authors:  C F Ihler
Journal:  Acta Vet Scand       Date:  1995       Impact factor: 1.695

5.  Probable reason why small strongyle EPG counts are returning "early" after ivermectin treatment of horses on a farm in Central Kentucky.

Authors:  E T Lyons; S C Tolliver; S S Collins
Journal:  Parasitol Res       Date:  2008-10-18       Impact factor: 2.289

6.  Moxidectin as an endectocide in reindeer.

Authors:  A Oksanen; M Nieminen
Journal:  Acta Vet Scand       Date:  1998       Impact factor: 1.695

Review 7.  Anthelmintic resistance in equine nematodes.

Authors:  Jacqueline B Matthews
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-10-25       Impact factor: 4.077

8.  Effect of Moxidectin on Bed Bug Feeding, Development, Fecundity, and Survivorship.

Authors:  Chen Zha; Changlu Wang; Johnathan Michael Sheele
Journal:  Insects       Date:  2017-09-30       Impact factor: 2.769

9.  Strongyle Infection and Gut Microbiota: Profiling of Resistant and Susceptible Horses Over a Grazing Season.

Authors:  Allison Clark; Guillaume Sallé; Valentine Ballan; Fabrice Reigner; Annabelle Meynadier; Jacques Cortet; Christine Koch; Mickaël Riou; Alexandra Blanchard; Núria Mach
Journal:  Front Physiol       Date:  2018-03-21       Impact factor: 4.566

10.  Integrative biology defines novel biomarkers of resistance to strongylid infection in horses.

Authors:  Guillaume Sallé; Cécile Canlet; Jacques Cortet; Christine Koch; Joshua Malsa; Fabrice Reigner; Mickaël Riou; Noémie Perrot; Alexandra Blanchard; Núria Mach
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.